Kornimate/medical-research-clean huggingface dataset:
effects of exercise on functional ability in people with dementia in nursing homes:a cluster randomised controlled trial

Conditions: Alzheimer Disease; Dementia

Summary: this is a cluster randomised controlled trial composed of two research arms: exercise training group (experimental group) and a social activity group (control group).

the recruitment process will be made only in nhs (nursing home) where the staff will have voluntarily accepted to participate in the study. we estimated to recruit 140 pwd (person with dementia) from around six-to-eight nhs (i.e., in average a minimum of 18 and a maximum of 24 pwd per nh). nhs constitute the unit of randomisation; nhs will be randomised to study groups using a 1:1 ratio (it means that all the participants living in a particular nh will participate in either the exercise training or the social activity). the randomisation will be stratified by the prevalence of dementia among nh residents; this stratification will provide homogeneity across research's arms, increasing thus the comparability among groups and producing then reliable results. randomisation will be done by a statistician not involved in the leden study. allocation concealment will be ensured by the use opaque sealed envelopes. the randomisation list will be kept in a electronic, password-locked file matching the name of participants to their research identification number and their group allocation. given the nature of the leden intervention (exercise training, i.e., a behavioural intervention) and since the main outcome measure, i.e., participants' ability in executing adls, of the the study requires that the outcome assessor knows how participants cope in their daily life, leden is a unblinded study

Eligibility criteria:
inclusion criteria: * confirmed diagnosis of alzheimer's disease, vascular or mixed dementia according to the criteria of the diagnostic and statistical manual of mental disorders, fourth edition (dsm-iv); * mmse ≤ 20 (out of 30); * living in one of the participating nhs for at least 3 months at the moment of baseline measurements (this time period will allow nh staff to have a good knowledge about the patient and about recent changes in his/her health status); * to be able of walking at least 4 meters (with walking devices if needed but without human assistance); * to be able to rise from a chair without help or with minimal human assistance. exclusion criteria: * mild dementia, illustrated by a mmse \> 20 (out of 30) * terminal illness with life expectancy less than 6 months; * diagnosis of parkinson's disease; * diagnosis of dementia with lewy bodies; * unstable cardiovascular condition or any other health condition that might be deteriorated by physical exercise; * planned transfer from the nh to another nh/home or to surgery during the 6-month period of intervention; * already participating in physical exercise ≥ 2 times/week in the last 2 months prior to the date of baseline assessments.

Keywords: alzheimer disease dementia physical activity functional ability disability functional limitation
disulfiram for cocaine-alcohol abuse - 3

Conditions: Alcohol-Related Disorders; Cocaine-Related Disorders

Summary: the purpose of this study is to evaluate disulfiram for cocaine-alcohol abuse.


Eligibility criteria:
please contact site for information.

Keywords: cocaine-related disorders
epidemiological study of quality of life in osteopathy

Conditions: Muscle Skeletal Disorders

Summary: aim of this study is to evaluate the effectiveness of osteopathy in changing quality of life in a large sample of naive patients undergoing osteopathic manipulative treatment.


Eligibility criteria:
inclusion criteria: * older than 18 years old * affected by muscle-skeletal disorder exclusion criteria: * younger than 18 years old * omt undertaken during the last 12 months * any manual therapy received during the last 12 months

Keywords: osteopathic manipulative treatment muscle-skeletal disorder quality of life
confocal laser endomicroscopy nodule localization by robotic bronchoscopy

Conditions: Lung Neoplasms

Summary: this study is designed to evaluate the safety and feasibility of real-time needle-based confocal laser endomicroscopy (ncle) in improving diagnostic accuracy of robotic-assisted bronchoscopy (ranb) biopsy performed with the monarch® endoscopy platform in patients with peripheral pulmonary nodules (ppn).

robotic-assisted navigational bronchoscopy (ranb) improves accuracy of lesion localization and diagnostic yield of the peripheral pulmonary nodule (ppn) biopsy compared to conventional flexible bronchoscopy. needle based confocal laser endomicroscopy (ncle) allows real-time microstructural imaging of lung nodule tissues at the needle tip. the study is designed to evaluate the safety and feasibility of utilizing ncle during ranb biopsy procedure to optimize needle position and diagnostic accuracy, as well as reduce or replace the need for additional imaging tools such as radial endobronchial ultrasound (r-ebus), cone beam computed tomography (cbct), and/or fluoroscopy during ranb biopsy.

Eligibility criteria:
inclusion criteria: * age ≥ 22 years at signing of informed consent form (icf). * undergoing standard-of-care ranb for a solid lung nodule, which is considered to be at intermediate- to high-risk for malignancy as determined by the investigator per the institution's standard of care. * icf signed before any study procedures are initiated. exclusion criteria: * medical contraindication to bronchoscopy under general anesthesia, or lack of physical fitness to undergo bronchoscopy under general anesthesia or to follow the study processes, as assessed by the investigator. * presence of uncorrectable bleeding disorders, or anticoagulation/anti-platelet aggregation therapy that cannot be withheld for an appropriate interval prior to the procedure, as defined per the institution's standard of care. * medical devices interfering with electro-magnetic navigation, including but not limited to pacemakers. * subjects who have a target lesion that shows endobronchial involvement on chest ct. * participation in any other clinical trial within 30 days of enrollment, that would interfere with this study. * known hypersensitivity to fluorescein sodium or any other ingredients in the fluorescein product. * planned surgical resection at the time of bronchoscopy * female subjects who are pregnant or nursing at the time of the procedure.

Keywords: peripheral pulmonary nodule needle-based confocal laser endomicroscopy robotic-assisted bronchoscopy monarch
appropriateness of methodist health system(mhs) inter-facility transfers of traumatic intracranial subarachnoid hemorrhage and spontaneous bleeds for level-1 advanced surgical intervention

Conditions: Traumatic Intracranial Subarachnoid Hemorrhage

Summary: brain injuries are common and challenging problems faced by emergency physicians. these diagnoses may include traumatic intracerebral hemorrhage, subarachnoid hemorrhage, ruptured cerebral aneurysms, unruptured cerebral aneurysms, and arteriovenous malformations, which require neurological, neurosurgical, and/or endovascular treatment.

brain injuries are common and challenging problems faced by emergency physicians. these diagnoses may include traumatic intracerebral hemorrhage, subarachnoid hemorrhage, ruptured cerebral aneurysms, unruptured cerebral aneurysms, and arteriovenous malformations, which require neurological, neurosurgical, and/or endovascular treatment. depending on the indication and its severity, transfer to a comprehensive stroke center for access to advanced neuro-critical care may be necessary. comprehensive stroke centers are widely supported and have the resources and infrastructure to have in-house expert stroke providers, teams, operating rooms, and interventional radiology suites that are always available.

Eligibility criteria:
inclusion criteria: * patients ≥18 years old * diagnosed with traumatic intracranial subarachnoid hemorrhage or a spontaneous bleed * patients originating at methodist mansfield medical center (mmmc) or methodist charlton medical center(mcmc)and subsequently transferred to methodist dallas medical center (mdmc) exclusion criteria: * does not meet inclusion criteria defined in section 3.1
development and validation of an orthopedic visit prompt list

Conditions: Musculoskeletal Diseases

Summary: investigators are interested to see whether patients who received a visit question prompt list before the consultation ask more questions, feel more actively involved in their healthcare, and think of their surgeon as being more empathetic.

visiting a doctor with a musculoskeletal problem can be quite a daunting experience for patients. a visit question prompt list may help to empower patients and increase their role in active decision-making. previous studies have shown that patient activation is correlated with a disability, pain intensity, and satisfaction with treatment. perceived empathy is strongly associated with satisfaction among people with arm problems. a list that prompts patients to ask about things that matter to them, might improve their connection with the surgeon and their perceived empathy. the investigators are interested to see whether patients who received a visit question prompt list before the consultation ask more questions, feel more actively involved in their healthcare, and think of their surgeon as being more empathetic.

Eligibility criteria:
inclusion criteria: * adult patients (18+) * orthopedic visit exclusion criteria: * patients who are illiterate. * patients who do not speak english.

Keywords: orthopedics
toss feasibility + fitbit community = reduced obesity in older black women

Conditions: Obesity

Summary: the primary goal of this proposed physical activity (pa) intervention is to develop a realistic and an economical intervention to promote regular pa among older, overweight or obese black women. physical inactivity is prevalent among older black women and this lifestyle behavior is both a destructive and expensive public health issue. because many in this population do not engage in sufficient amounts of regular pa, this group miss the cardio-protective effects that may reduce many chronic conditions that disproportionately affect blacks such as hypertension, diabetes, and obesity. the proposed obesity-reduction intervention is aligned with stage 1 of the national institute on aging stage model for behaviors interventions development. for the proposed hypothesis, the investigators propose a 2-group randomized controlled pilot, feasibility study in which 30 women will be randomized to receive either the toss pa text messages plus fitbit community or the control group and followed for 12 weeks to detect intervention effect.


Eligibility criteria:
inclusion criteria: * black women * 60 years and older * have a bmi ≥ 25 kg/m2 * do not meet the weekly 150 minutes of physical activity (pa) * no health conditions that would prevent or limit pa or walking * able to read text messages * access to a mobile phone with text receiving capability * mobile phone with ability to download a fitbit app. exclusion criteria: * currently participating in another pa promotion program * non-english speaking * a contraindication to exercise as indicated by the pa readiness questionnaire (par-q) unless written permission was provided from the participant's primary care provider.

Keywords: physical activity older black women overweight obesity text messages
comparison of steroid dosages on the efficacy of trochanteric bursa injection

Conditions: Bursitis

Summary: inflammation of the trochanteric bursa is a common cause of hip pain. a bursa is a closed fluid filled sac or sac-like cavity found between tissues that function as a gliding surface to reduce friction. bursitis is the inflammation of the bursa. inflammation between the trochanteric process of the femur and gluteus medius tendon/ iliotibial tract is the cause of trochanteric bursitis. several treatments exist for trochanteric bursitis, including a local steroid injection. the injection consists of a mixture of local anesthetic and steroid medications. the steroid is routinely mixed with a local anesthetic. the anesthetic acts to diluent the steroid as well as act as a pain reliever. various steroid preparations have been used, at varying doses, for trochanteric bursitis. the steroid preparation, triamcinolone is commonly used for various reasons. besides the procedure associated and injection site risks, risks associated with the use of steroids, though rare, exist. short term, the steroid can raise blood sugar levels and should be used with caution and be appropriately monitored in diabetics. additionally, the steroid can suppress the immune system. long-term risks are related to the dose and frequency of use. these risks include thinning of the skin, easy bruising, weight gain, elevated blood pressure, cataract formation, thinning of bones and joints. studies have shown the effectiveness of local steroid injections for trochanteric bursitis. unfortunately, there is limited data on the ideal dose of the steroid preparation. triamcinolone of 40mg/ ml is commonly used, but, studies have shown effectiveness at various doses, ranging 20 to 160 mg/ml. the aim of this study is to evaluate and compare the effectiveness of local steroid injections of various steroid dosages for the treatment of trochanteric bursitis.


Eligibility criteria:
inclusion criteria: 1. clinical diagnosis of trochanteric bursitis 2. 18 years of age or older when written informed consent is obtained 3. signed institutional review board approved informed consent form exclusion criteria: 1. meets any contraindication for treatment 2. allergy to triamcinolone, lidocaine 3. previous surgery to bursa 4. coagulopathy 5. active infection 6. currently diagnosed with cognitive impairment, or exhibits any characteristic, that would limit study candidate's ability to assess pain relief or complete study assessments
evaluation of respiratory parameters in patients with upper limb lymphedema

Conditions: Lymphedema of Upper Limb

Summary: the aim of our study is to assess disease severity, respiratory muscle strength, respiratory functions, pectoralis minor muscle shortening, functionality, and quality of life (qol) in patients with upper limb lymphedema (ull), and to compare these findings with healthy controls.the disease severity was assessed using the stillwell classification system; respiratory muscle strength was measured through maximum inspiratory and expiratory intraoral pressures (mip, mep, respectively); respiratory functions were evaluated with a spirometer; pectoralis minor muscle shortening was measured with a tape measure; functionality was assessed using the disabilities of the arm, shoulder and hand (dash); and qol was evaluated with the lymphedema quality of life questionnaire - arm (lymqol-arm).

the study had a cross-sectional observational study design. the participants were divided into two groups, patients with ull in group 1; the healthy individuals were included in group 2. all assessments for both groups were performed by two different physiotherapists.

Eligibility criteria:
inclusion criteria: * aged 25-65 years with secondary, unilateral upper limb lymphedema in phase 2 of the protection stage, * wearing compression garments, * who have not received manual lymph drainage (mld) therapy in the last 3 months * along with healthy controls of a similar age who volunteered to participate. exclusion criteria: * being in phase 1 of lymphedema treatment (the edema-reducing phase), * being classified as nyha class iii and/or iv according to the new york heart association classification system, * having a chronic respiratory disease, * presence of active infection (such as lymphangitis or cellulitis), or undergoing radiotherapy/chemotherapy due to breast cancer.

Keywords: lymphedema upper limb quality of life respiratory function test
the evaluation of the effectiveness and safety of nalbuphine hydrochloride injection for analgesia in icu patients: a multicenter, randomized, single-blinded, parallel, two-step trial

Conditions: Respiratory Insufficiency

Summary: the analgesic effect of nalbuphine hydrochloride injection will be evaluated in a multicenter, randomized, single-blind, parallel, positive-controlled approach in two steps: step 1, to explore the optimal dosage of nalbuphine hydrochloride injection with 2 experimental arms and 1 positive control and step 2, to evaluate the effectiveness and safety of nalbuphine hydrochloride injection in mechanically ventilated icu patients at a dosage determined in step 1 with the same positive control.


Eligibility criteria:
inclusion criteria: 1. icu patients who are intubated are expected to require mechanical ventilation for more than 6h 2. patients or their guardians have a full understanding of the purpose and significance of this trial, and voluntarily participate in this clinical trial and sign an informed consent form exclusion criteria: 1. allergy or unsuitability to any composition of study drugs or propofol 2. living expectancy of less than 48 hours 3. neurological disorder and any other condition interfering with sedation assessment 4. gastrointestinal obstruction 5. asthmatic 6. abdominal compartment syndrome 7. serious hepatic dysfunction (ctp 10-15) 8. acute kidney injury (kdigo stage 2 or 3) or chronic kidney disease with glomerular filtration rate (gfr) \< 29 ml/min/1.73m2 9. circulatory instability (the need for a continuous infusion of norepinephrine at ≥0.5 ug/kg/min to maintain proper blood pressure) 10. need deep sedation or paralytics 11. anticipation to receive operations (including tracheotomy) 12. abuse of controlled substances or alcohol 13. pregnancy, lactation, or an intention of gestation in 6 months 14. inclusion in another interventional trial in the past 30 days 15. other conditions deemed unsuitable to be included
regorafenib combined with irinotecan drug-eluting beads for colorectal cancer liver metastases

Conditions: Colorectal Cancer Liver Metastases; Regorafenib

Summary: this study is a multicentre, prospective, randomised trial, aims to evaluate the efficacy and safety of irinotecan drug-eluting beads combined with regorafenib as the third-line treatment for a patient with colorectal cancer liver metastases. the study is planned to enrolled 126 patients failing first- and second-line standard chemotherapy treatment.


Eligibility criteria:
inclusion criteria: * patients over 18 years of age, of any race or sex, who have histologic or radiologic proof of colorectal cancer to the liver, who are able to give informed consent, will be eligible. * patients failing first- and second-line standard systemic chemotherapy. * patients with at least one measurable liver metastases, with size \> 1cm response evaluation criteria in solid tumors (recist) * patients with liver dominant disease defined as ≥80% tumor body burden confined to the liver * less than 60% liver tumor replacement * eastern cooperative oncology group (ecog) performance status score of \< 2 * child-pugh's grade a or b * life expectancy of \> 3 months * non-pregnant with an acceptable contraception in premenopausal women. * hematologic function: absolute neutrophil count (anc) ≥ 1.5 x 109/l, white cell count (wbc) ≥ 3.0 x 109/l, platelets ≥75 x109/l, international normalized ratio (inr) ≤1.3. * adequate hepatic and renal function: alanine aminotransferase (alt) or aspartate aminotransferase ≤2.5×above upper normal range, total bilirubin≤1.5×above upper normal range, serum creatinine≤1.5×above upper normal range * women of child bearing potential and fertile men are required to use effective contraception negative serum beta human chorionic gonadotropin (βhcg) * signed, written informed consent exclusion criteria: * prior treatment with tace, regorafenib or fruquintinib * patients with brain metastases * with serious heart, kidney, bone marrow, or lung, central nervous system diseases. * patients suffered with other cancer. * patients who were seriously ill and had history of chronic disease such as tuberculosis (tb) and human immunodeficiency virus (hiv)/acquired immune deficiency syndrome (aids) were excluded from the study. * known or suspected history of allergy to any of the related drugs used in the study * women who are pregnant or breast feeding * patients with serious somatic or psychiatric illness regarded as contraindications or in need of treatment that would interfere with study participation.
genomic study of cutis tricolor

Conditions: Pigmentary; Dermatosis

Summary: it's a study on syndromic or isolated cutis tricolor and had as main goal to identify the associated gene to the disease thanks to genetic analysis on minors patients and their parents reach by cutis tricolor or not.

cutis tricolor (ct) is a rare cutaneous anomaly defined by pigmentary disorders associating large hyper- and hypopigmented macules of immediate proximity, selectively affecting the trunk. ct can be isolated, sporadic or integrated as a complex syndromic form such as ruggieri-happle syndrome (rhs) or various forms of pigmentovascular phacomatosis. a recent analysis of one case of rhs followed by chu of montpellier by whole exome sequencing allows the identification of a frameshift pathogen variant (heterozygous state) of a candidate gene. the main objective is to confirm the association of the candidate gene with syndromic ct (sct, ruggierri-happle syndrome) and non syndromic ct, from a genetic molecular blood and biopsy analysis of patients reach by ct and their parents presenting the disease or not. furthermore, other objectives are to identify others associated candidates genes and to know better cutaneous pigmentary troubles factors, neurologics and eye abnormalities by identifying the differents cellulars pathways particularly the inflammatory pathway in the pathology of sct. first of all, it will have a pre-inclusion visit where dr willems. m (clinical genetic department - chu montpellier, france) and pr bessis. d (dermatology department - chu montpellier, france) will explain the study's progress. then, during the inclusion visit, families will sign inform consent for inclusion in the study. the same day, datas will be collected on demographic, clinical datas, including (i) a description of cutaneous, morphologic and extra-cutaneous anomalies and (ii) a cutaneous biopsy and (iii) a blood test will be done. the genetics exams results will be return to patients during an usual follow-up visit, 12 months after their inclusion in the study.

Eligibility criteria:
inclusion criteria: * patients with cutis tricolor in trio (an affected parent, an unaffected parent) or in duo (one of the two affected parents) * age : from 4 to 60 years exclusion criteria: * refusal to sign the informed consent * patient who doesn't have a social security scheme or beneficiary of such a scheme * pregnant or breastfeeding women * patient whith a legal protection measure (guardianship, curatorship) * patient under legal protection